U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C15H13FO2
Molecular Weight 244.2609
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FLURBIPROFEN

SMILES

CC(C(O)=O)C1=CC(F)=C(C=C1)C2=CC=CC=C2

InChI

InChIKey=SYTBZMRGLBWNTM-UHFFFAOYSA-N
InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)

HIDE SMILES / InChI

Molecular Formula C15H13FO2
Molecular Weight 244.2609
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory drug that exhibits antiinflammatory, analgesic, and antipyretic activities in animal models. Flurbiprofen Tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis and for relief of the signs and symptoms of osteoarthritis. It may also be used to treat pain associated with dysmenorrhea and mild to moderate pain accompanied by inflammation (e.g. bursitis, tendonitis, soft tissue trauma). Flurbiprofen may also be used topically prior to ocular surgery to prevent or reduce intraoperative miosis. Similar to other NSAIAs, the anti-inflammatory effect of flurbiprofen occurs via reversible inhibition of cyclooxygenase (COX), the enzyme responsible for the conversion of arachidonic acid to prostaglandin G2 (PGG2) and PGG2 to prostaglandin H2 (PGH2) in the prostaglandin synthesis pathway. This effectively decreases the concentration of prostaglandins involved in inflammation, pain, swelling and fever. Flurbiprofen is a non-selective COX inhibitor and inhibits the activity of both COX-1 and -2. It is also one of the most potent NSAIAs in terms of prostaglandin inhibitory activity.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
0.11 µM [IC50]
6.46 µM [IC50]
0.2 µM [IC50]
0.91 µM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Flurbiprofen
Primary
Flurbiprofen
Primary
LOQOA® Tape

Cmax

ValueDoseCo-administeredAnalytePopulation
14 μg/mL
100 mg single, oral
FLURBIPROFEN plasma
Homo sapiens
19.67 μg/mL
150 mg single, oral
FLURBIPROFEN plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
83 μg × h/mL
100 mg single, oral
FLURBIPROFEN plasma
Homo sapiens
124.2 μg × h/mL
150 mg single, oral
FLURBIPROFEN plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
7.5 h
100 mg single, oral
FLURBIPROFEN plasma
Homo sapiens
4.77 h
150 mg single, oral
FLURBIPROFEN plasma
Homo sapiens

Drug as perpetrator​

Drug as victim

PubMed

Sample Use Guides

In Vivo Use Guide
Loqoa® is available as a patch formulation, containing 40 mg of Esflurbiprofen. The recommended dose is applied to the lesion area once daily. Do not apply more than two patches simultaneously.
Route of Administration: Topical
In Vitro Use Guide
At 100 uM concentration Esflurbiprofen (S-Flurbiprofen) demonstrated 37% inhibition of Abeta42 in SH-SY5Y cells and 65% in HEK cells.
Substance Class Chemical
Record UNII
5GRO578KLP
Record Status Validated (UNII)
Record Version